肺気腫治療市場：タイプ別、治療法別、患者タイプ別、ケア環境別、投与経路別-2025-2030年の世界予測

肺気腫治療市場は、2023年に64億米ドルと評価され、2024年には68億3,000万米ドルに達すると予測され、CAGR 6.98％で成長し、2030年には102億7,000万米ドルに達すると予測されています。

肺気腫治療市場の範囲と定義は、主に損傷した気嚢と気流の閉塞を特徴とする、この慢性的で不可逆的な肺疾患の管理を目的とした幅広い医療介入を包含します。肺気腫は生活の質を著しく損なうため、症状を緩和し呼吸機能を高める治療が必要となります。気管支拡張薬やコルチコステロイドなどの薬理学的アプローチと、肺活量減少手術などの外科的介入の両方が応用されます。最終用途には、病院、診療所、在宅ヘルスケアなどが含まれます。主な成長促進要因としては、高齢化や汚染レベルの上昇による慢性閉塞性肺疾患（COPD）の有病率の増加、薬剤開発の進歩、低侵襲手術に対する患者の嗜好の高まりなどが挙げられます。しかし、潜在的な成長機会は、新興国市場におけるヘルスケアインフラの拡大や、再生医療やAI技術によって強化された個別化治療計画などの新規治療の開拓にあります。市場の限界に対処するための課題は、主に厳しい規制要件、先進的な治療法に関連する高コスト、呼吸器疾患の臨床試験を実施する際の特有の複雑さに起因します。特定の地域における経済的不安定も、市場拡大を阻害する可能性があります。革新的な研究開発分野としては、呼吸器の健康状態をモニターするウェアラブル技術の開発、遠隔患者管理を容易にする遠隔医療の進歩、早期診断とオーダーメイド治療を可能にするバイオマーカーの発見などが挙げられます。市場はダイナミックであり、技術的進歩や、全人的で患者中心のケアモデルへのシフトに大きな注目が集まっています。事業成長を目指す企業は、研究開発に投資して課題を軽減し、新たな機会を活用すべきです。製薬企業、ヘルスケアプロバイダー、テクノロジー企業のコラボレーションはイノベーションを加速し、市場への浸透と患者の転帰改善につながる可能性があります。市場が世界的に拡大し続ける中、費用対効果が高く、利用しやすい治療オプションを重視することは極めて重要です。

市場力学：急速に進化する肺気腫治療市場の主要市場インサイトを公開

肺気腫治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 喫煙率の増加と汚染レベルの上昇が肺気腫の発生率の上昇に寄与
  • 肺気腫の早期発見と治療を促進する診断技術とテクノロジーの進歩
  • 高齢者人口の増加と高齢者における呼吸器疾患への高い感受性
  • 肺気腫の高度な治療選択肢を支えるヘルスケア支出の増加と政府の取り組み
• 市場抑制要因
  • 新薬や新デバイスに対する厳しい規制当局の承認プロセスによる市場参入の遅れ
  • 地方における肺気腫の認知度と診断率の低さが市場成長の阻害要因
• 市場機会
  • 肺気腫管理のための低侵襲外科治療への嗜好の高まり
  • 標的を絞った先進的ドラッグデリバリーシステムに対する需要の高まり肺気腫治療
  • 肺気腫の早期発見のための認識向上とスクリーニングプログラム
• 市場の課題
  • 市場に参入する新しい肺気腫治療療法に対する規制上のハードルと長い承認期間
  • 複雑な投与要件のため、処方された治療レジメンに対する患者のアドヒアランスが低い

ポーターの5つの力：肺気腫治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：肺気腫治療市場における外部からの影響の把握

外部マクロ環境要因は、肺気腫治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析肺気腫治療市場における競合情勢の把握

肺気腫治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス肺気腫治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、肺気腫治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨肺気腫治療市場における成功への道筋を描く

肺気腫治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 喫煙率の増加と大気汚染レベルの上昇が肺気腫の発生率増加につながっている
    • 肺気腫の早期発見と治療を促進する診断技術とテクノロジーの進歩
    • 高齢者人口の増加と高齢者の呼吸器疾患に対する感受性の高まり
    • ヘルスケア費の増加と肺気腫の先進的治療オプションを支援する政府の取り組み
  • 抑制要因
    • 新しい肺気腫治療医薬品や医療機器に対する厳格な規制承認プロセスにより、市場参入が遅れる
    • 地方における肺気腫の認知度と診断率の低さが市場の成長を妨げている
  • 機会
    • 肺気腫治療における低侵襲性外科治療の好感度が高まっている
    • 標的を絞った高度なドラッグデリバリーシステムに対する需要の高まり肺気腫治療
    • 肺気腫の早期発見に向けた意識向上とスクリーニングプログラム
  • 課題
    • 市場に参入する新しい肺気腫治療治療法に対する規制上のハードルと長い承認時間
    • 複雑な投与要件により、処方された治療計画に対する患者の遵守率が低い
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 肺気腫治療市場：タイプ別

• 吸入薬
  • 抗コリン薬
  • 長時間作用型ベータ刺激薬（LABA）
  • 短時間作用型ベータ刺激薬（SABA）
• 静脈内投与薬
• 経口薬
  • コルチコステロイド
  • ホスホジエステラーゼ4阻害剤（PDE4阻害剤）

第7章 肺気腫治療市場治療別

• 医薬品
  • 気管支拡張薬
  • ステロイド
• 手術
  • 肺移植
  • 肺容量減少手術
• 治療法
  • 酸素療法
  • 呼吸リハビリテーション

第8章 肺気腫治療市場患者タイプ別

• 成人用
• 高齢者
• 小児科

第9章 肺気腫治療市場ケア設定別

• クリニック
• ホームケア
• 病院

第10章 肺気腫治療市場：投与経路別

• 吸入
• オーラル
• 非経口

第11章 南北アメリカの肺気腫治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の肺気腫治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの肺気腫治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 1. AbbVie Inc.
• 2. AstraZeneca plc
• 3. Bayer AG
• 4. Boehringer Ingelheim International GmbH
• 5. Chiesi Farmaceutici S.p.A.
• 6. Cipla Limited
• 7. CSL Limited
• 8. Eli Lilly and Company
• 9. F. Hoffmann-La Roche AG
• 10. GlaxoSmithKline plc
• 11. Grifols S.A.
• 12. Merck & Co., Inc.
• 13. Mylan N.V.
• 14. Novartis International AG
• 15. Pfizer Inc.
• 16. Sanofi S.A.
• 17. Sumitomo Dainippon Pharma Co., Ltd.
• 18. Sun Pharmaceutical Industries Ltd.
• 19. Takeda Pharmaceutical Company Limited
• 20. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

• FIGURE 1. EMPHYSEMA TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. EMPHYSEMA TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EMPHYSEMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. EMPHYSEMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. EMPHYSEMA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. EMPHYSEMA TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ANTICHOLINERGICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LONG-ACTING BETA-AGONISTS (LABAS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SHORT-ACTING BETA-AGONISTS (SABAS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INTRAVENOUS DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PHOSPHODIESTERASE-4 INHIBITORS (PDE4 INHIBITORS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY BRONCHODILATORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY STEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY LUNG VOLUME REDUCTION SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY OXYGEN THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PULMONARY REHABILITATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL EMPHYSEMA TREATMENT MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 57. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 58. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 66. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 67. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 68. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 73. BRAZIL EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 76. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 77. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 78. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 79. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 80. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 81. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 82. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 83. CANADA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 84. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 86. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 87. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 88. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 89. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 91. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 92. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 93. MEXICO EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 96. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 97. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 98. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 99. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 103. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 104. UNITED STATES EMPHYSEMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 105. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 107. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 108. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 109. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 110. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 114. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 116. AUSTRALIA EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. AUSTRALIA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 118. AUSTRALIA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 119. AUSTRALIA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 120. AUSTRALIA EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 121. AUSTRALIA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 122. AUSTRALIA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 123. AUSTRALIA EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 124. AUSTRALIA EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 125. AUSTRALIA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 126. CHINA EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. CHINA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 128. CHINA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 129. CHINA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 130. CHINA EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 131. CHINA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 132. CHINA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 133. CHINA EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 134. CHINA EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 135. CHINA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 136. INDIA EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. INDIA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 138. INDIA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 139. INDIA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 140. INDIA EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 141. INDIA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 142. INDIA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 143. INDIA EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 144. INDIA EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 145. INDIA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 146. INDONESIA EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. INDONESIA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 148. INDONESIA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 149. INDONESIA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 150. INDONESIA EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 151. INDONESIA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 152. INDONESIA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 153. INDONESIA EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 154. INDONESIA EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 155. INDONESIA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 156. JAPAN EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 157. JAPAN EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 158. JAPAN EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 159. JAPAN EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 160. JAPAN EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 161. JAPAN EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 162. JAPAN EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 163. JAPAN EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 164. JAPAN EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 165. JAPAN EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 166. MALAYSIA EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 167. MALAYSIA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 168. MALAYSIA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 169. MALAYSIA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 170. MALAYSIA EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 171. MALAYSIA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 172. MALAYSIA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 173. MALAYSIA EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 174. MALAYSIA EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 175. MALAYSIA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 176. PHILIPPINES EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 177. PHILIPPINES EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 178. PHILIPPINES EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 179. PHILIPPINES EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 180. PHILIPPINES EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 181. PHILIPPINES EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 182. PHILIPPINES EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 183. PHILIPPINES EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 184. PHILIPPINES EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 185. PHILIPPINES EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 186. SINGAPORE EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 187. SINGAPORE EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 188. SINGAPORE EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 189. SINGAPORE EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 190. SINGAPORE EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 191. SINGAPORE EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 192. SINGAPORE EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 193. SINGAPORE EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 194. SINGAPORE EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 195. SINGAPORE EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 196. SOUTH KOREA EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 197. SOUTH KOREA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 198. SOUTH KOREA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH KOREA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH KOREA EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH KOREA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH KOREA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH KOREA EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 204. SOUTH KOREA EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 205. SOUTH KOREA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 206. TAIWAN EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 207. TAIWAN EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 208. TAIWAN EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 209. TAIWAN EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 210. TAIWAN EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 211. TAIWAN EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 212. TAIWAN EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 213. TAIWAN EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 214. TAIWAN EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 215. TAIWAN EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 216. THAILAND EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 217. THAILAND EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 218. THAILAND EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 219. THAILAND EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 220. THAILAND EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 221. THAILAND EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 222. THAILAND EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 223. THAILAND EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 224. THAILAND EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 225. THAILAND EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 226. VIETNAM EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 227. VIETNAM EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 228. VIETNAM EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 229. VIETNAM EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 230. VIETNAM EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 231. VIETNAM EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 232. VIETNAM EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 233. VIETNAM EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 234. VIETNAM EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 235. VIETNAM EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 236. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 237. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 238. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 239. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 240. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA EMPHYSEMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 247. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 248. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 249. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 250. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 251. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 252. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 253. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 254. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 255. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 256. DENMARK EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 257. EGYPT EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 258. EGYPT EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 259. EGYPT EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 260. EGYPT EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 261. EGYPT EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 262. EGYPT EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 263. EGYPT EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 264. EGYPT EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 265. EGYPT EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 266. EGYPT EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 267. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 268. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 269. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 270. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 271. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 272. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 273. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 274. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 275. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 276. FINLAND EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 277. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 278. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 279. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 280. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 281. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 282. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 283. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 284. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 285. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 286. FRANCE EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 287. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 288. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 289. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 290. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 291. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 292. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 293. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 294. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 295. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 296. GERMANY EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 297. ISRAEL EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 298. ISRAEL EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 299. ISRAEL EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 300. ISRAEL EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 301. ISRAEL EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 302. ISRAEL EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 303. ISRAEL EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 304. ISRAEL EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 305. ISRAEL EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 306. ISRAEL EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 307. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 308. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 309. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 310. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 311. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 312. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 313. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 314. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 315. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 316. ITALY EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 317. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 318. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 319. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 320. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 321. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 322. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 323. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 324. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 325. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 326. NETHERLANDS EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 327. NIGERIA EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 328. NIGERIA EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 329. NIGERIA EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 330. NIGERIA EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 331. NIGERIA EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 332. NIGERIA EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 333. NIGERIA EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 334. NIGERIA EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 335. NIGERIA EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 336. NIGERIA EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 337. NORWAY EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 338. NORWAY EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 339. NORWAY EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL DRUGS, 2018-2030 (USD MILLION)
• TABLE 340. NORWAY EMPHYSEMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 341. NORWAY EMPHYSEMA TREATMENT MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
• TABLE 342. NORWAY EMPHYSEMA TREATMENT MARKET SIZE, BY SURGERIES, 2018-2030 (USD MILLION)
• TABLE 343. NORWAY EMPHYSEMA TREATMENT MARKET SIZE, BY THERAPIES, 2018-2030 (USD MILLION)
• TABLE 344. NORWAY EMPHYSEMA TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
• TABLE 345. NORWAY EMPHYSEMA TREATMENT MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
• TABLE 346. NORWAY EMPHYSEMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 347. POLAND EMPHYSEMA TREATMENT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 348. POLAND EMPHYSEMA TREATMENT MARKET SIZE, BY INHALATION DRUGS, 2018-2030 (USD MILLION)
• TABLE 349. POLAND EMPHYSEMA TREATMENT MARKET SIZE, BY ORAL

The Emphysema Treatment Market was valued at USD 6.40 billion in 2023, expected to reach USD 6.83 billion in 2024, and is projected to grow at a CAGR of 6.98%, to USD 10.27 billion by 2030.

The scope and definition of the emphysema treatment market encompass a range of medical interventions aimed at managing this chronic, irreversible lung condition, primarily characterized by damaged air sacs and obstructed airflow. Necessity arises as emphysema significantly impairs quality of life, demanding treatments that alleviate symptoms and enhance respiratory function. Applications involve both pharmacological approaches, such as bronchodilators and corticosteroids, and surgical interventions, like lung volume reduction surgery. The end-use scope includes hospitals, clinics, and home healthcare settings. Key growth drivers include an increasing prevalence of chronic obstructive pulmonary disease (COPD) due to aging populations and rising pollution levels, alongside advances in drug development and increasing patient preference for minimally invasive procedures. However, potential growth opportunities lie in expanding healthcare infrastructure in emerging markets and the development of novel therapies, such as regenerative medicines or personalized treatment plans bolstered by AI technologies. Addressing market limitations, challenges primarily stem from stringent regulatory requirements, high costs associated with advanced treatment modalities, and the inherent complexities of conducting clinical trials for respiratory diseases. Economic instability in certain regions could also impede market expansion. Innovative research areas include the development of wearable technology to monitor respiratory health, advances in telemedicine to facilitate remote patient management, and biomarker discovery to enable earlier diagnosis and tailored therapies. The market is dynamic, with a significant focus on technological advancements and a shift towards holistic and patient-centric care models. Companies aiming for business growth should invest in R&D to mitigate challenges and capitalize on emerging opportunities. Collaborations between pharmaceutical firms, healthcare providers, and technology companies could accelerate innovation, leading to better market penetration and improved patient outcomes. Emphasizing cost-effective and accessible treatment options will be crucial as the market continues to expand globally.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Emphysema Treatment Market

The Emphysema Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of smoking and rising pollution levels contributing to higher instances of emphysema
  • Advancements in diagnostic techniques and technologies facilitating early detection and treatment of emphysema
  • Growing geriatric population and higher susceptibility to respiratory diseases among the elderly
  • Rising healthcare expenditure and government initiatives supporting advanced treatment options for emphysema
• Market Restraints
  • Stringent regulatory approvals process for new emphysema treatment drugs and devices causes delays in market entry
  • Low awareness and diagnosis rates of emphysema in rural areas hinder market growth
• Market Opportunities
  • Increasing preference for minimally invasive surgical treatments for emphysema management
  • Growing demand for advanced drug delivery systems for targeted emphysema treatment
  • Rising awareness and screening programs for early detection of emphysema
• Market Challenges
  • Regulatory hurdles and long approval times for new emphysema treatment therapies entering the market
  • Low patient adherence to prescribed treatment regimens due to complicated administration requirements

Porter's Five Forces: A Strategic Tool for Navigating the Emphysema Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Emphysema Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Emphysema Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Emphysema Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Emphysema Treatment Market

A detailed market share analysis in the Emphysema Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Emphysema Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Emphysema Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Emphysema Treatment Market

A strategic analysis of the Emphysema Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Emphysema Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., Cipla Limited, CSL Limited, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Grifols S.A., Merck & Co., Inc., Mylan N.V., Novartis International AG, Pfizer Inc., Sanofi S.A., Sumitomo Dainippon Pharma Co., Ltd., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Emphysema Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Inhalation Drugs, Intravenous Drugs, and Oral Drugs. The Inhalation Drugs is further studied across Anticholinergics, Long-acting Beta-agonists (LABAs), and Short-acting Beta-agonists (SABAs). The Oral Drugs is further studied across Corticosteroids and Phosphodiesterase-4 inhibitors (PDE4 Inhibitors).
• Based on Treatment, market is studied across Medications, Surgeries, and Therapies. The Medications is further studied across Bronchodilators and Steroids. The Surgeries is further studied across Lung Transplant and Lung Volume Reduction Surgery. The Therapies is further studied across Oxygen Therapy and Pulmonary Rehabilitation.
• Based on Patient Type, market is studied across Adult, Geriatric, and Pediatric.
• Based on Care Settings, market is studied across Clinics, Home Care, and Hospitals.
• Based on Route of Administration, market is studied across Inhalation, Oral, and Parenteral.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of smoking and rising pollution levels contributing to higher instances of emphysema
    • 5.1.1.2. Advancements in diagnostic techniques and technologies facilitating early detection and treatment of emphysema
    • 5.1.1.3. Growing geriatric population and higher susceptibility to respiratory diseases among the elderly
    • 5.1.1.4. Rising healthcare expenditure and government initiatives supporting advanced treatment options for emphysema
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent regulatory approvals process for new emphysema treatment drugs and devices causes delays in market entry
    • 5.1.2.2. Low awareness and diagnosis rates of emphysema in rural areas hinder market growth
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing preference for minimally invasive surgical treatments for emphysema management
    • 5.1.3.2. Growing demand for advanced drug delivery systems for targeted emphysema treatment
    • 5.1.3.3. Rising awareness and screening programs for early detection of emphysema
  • 5.1.4. Challenges
    • 5.1.4.1. Regulatory hurdles and long approval times for new emphysema treatment therapies entering the market
    • 5.1.4.2. Low patient adherence to prescribed treatment regimens due to complicated administration requirements
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Emphysema Treatment Market, by Type

• 6.1. Introduction
• 6.2. Inhalation Drugs
  • 6.2.1. Anticholinergics
  • 6.2.2. Long-acting Beta-agonists (LABAs)
  • 6.2.3. Short-acting Beta-agonists (SABAs)
• 6.3. Intravenous Drugs
• 6.4. Oral Drugs
  • 6.4.1. Corticosteroids
  • 6.4.2. Phosphodiesterase-4 inhibitors (PDE4 Inhibitors)

7. Emphysema Treatment Market, by Treatment

• 7.1. Introduction
• 7.2. Medications
  • 7.2.1. Bronchodilators
  • 7.2.2. Steroids
• 7.3. Surgeries
  • 7.3.1. Lung Transplant
  • 7.3.2. Lung Volume Reduction Surgery
• 7.4. Therapies
  • 7.4.1. Oxygen Therapy
  • 7.4.2. Pulmonary Rehabilitation

8. Emphysema Treatment Market, by Patient Type

• 8.1. Introduction
• 8.2. Adult
• 8.3. Geriatric
• 8.4. Pediatric

9. Emphysema Treatment Market, by Care Settings

• 9.1. Introduction
• 9.2. Clinics
• 9.3. Home Care
• 9.4. Hospitals

10. Emphysema Treatment Market, by Route of Administration

• 10.1. Introduction
• 10.2. Inhalation
• 10.3. Oral
• 10.4. Parenteral

11. Americas Emphysema Treatment Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Emphysema Treatment Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Emphysema Treatment Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. AstraZeneca plc
• 3. Bayer AG
• 4. Boehringer Ingelheim International GmbH
• 5. Chiesi Farmaceutici S.p.A.
• 6. Cipla Limited
• 7. CSL Limited
• 8. Eli Lilly and Company
• 9. F. Hoffmann-La Roche AG
• 10. GlaxoSmithKline plc
• 11. Grifols S.A.
• 12. Merck & Co., Inc.
• 13. Mylan N.V.
• 14. Novartis International AG
• 15. Pfizer Inc.
• 16. Sanofi S.A.
• 17. Sumitomo Dainippon Pharma Co., Ltd.
• 18. Sun Pharmaceutical Industries Ltd.
• 19. Takeda Pharmaceutical Company Limited
• 20. Teva Pharmaceutical Industries Ltd.